- Brand names:
- Pharmaceutical Company:
- Condition/Indication:
- Meeting Date: November 2017
- Public Summary Document (PSD) November 2017 PBAC Meeting - PDF
- Public Summary Document (PSD) November 2017 PBAC Meeting - Word
Ponatinib – November 2017
Ponatinib: Tablet 15 mg (as hydrochloride), Tablet 45 mg (as hydrochloride); Inclusig®
Last updated
9 November 2018